CDMO revenue growth mid-single-digit in FY26
Management guided for mid-single-digit revenue growth in CDMO for FY26, down from earlier mid-to-high single-digit guidance, due to continued API price softness.
AKUMS / guidance tracker
Keep management guidance in view.
Akums Drugs and Pharmaceuticals · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
European contract commercial supplies from April 2027
Commercial supplies for the European CDMO contract will begin in April 2027, with an annual revenue run-rate of at least ₹300 crore.
Target $100 million formulation exports in 5 years
Management targets $100 million in total formulation exports (including international branded and CDMO) over the next five years, up from current ~$15 million run-rate.
Domestic branded formulation margins at ~18% for FY26
CFO stated that domestic branded formulation EBITDA margins are expected to remain similar to last year at around 18% for the full year.